Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial

INTRODUCTION: Despite extensive multidisciplinary team (MDT) assessment, some patients have interstitial lung disease (ILD) that is considered unclassifiable (uILD), for which there are currently no approved treatments. This study will assess the efficacy and safety of the antifibrotic pirfenidone i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMJ Open Respir Res
Main Authors: Maher, Toby M, Corte, Tamera J, Fischer, Aryeh, Kreuter, Michael, Lederer, David J, Molina-Molina, Maria, Axmann, Judit, Kirchgaessler, Klaus-Uwe, Cottin, Vincent
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2018
Assuntos:
Interstitial Lung Disease
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6135451/
https://ncbi.nlm.nih.gov/pubmed/30233802
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjresp-2018-000289
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados